---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-108914"
form_type: "8-K"
ticker: "ELAN"
cik: "0001739104"
company_name: "Elanco Animal Health Inc"
filed_at: "2024-10-16T23:59:59+00:00"
generated_at: "2026-05-30T13:52:57.689948+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Elanco presents Zenrelia study showing similar serologic response; approved in Canada

## Summary
- Study presented at ISCAID: 68 beagles given ilunocitinib at 1X or 3X label dose for 56 days; protective titer levels post-booster similar to control group.
- No serious adverse events observed; supports safety of Zenrelia concurrent with core booster vaccinations including rabies.
- Zenrelia (ilunocitinib) received regulatory approval in Canada; further details on Health Canada Drug Product Database.

## SEC filing metadata
- accession: 0001104659-24-108914
- form_type: 8-K
- ticker: ELAN
- cik: 0001739104
- company_name: Elanco Animal Health Inc
- filed_at: 2024-10-16T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1739104/000110465924108914/0001104659-24-108914-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1739104/000110465924108914/tm2425466d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-108914
- JSON: https://secwatch.observer/filing/0001104659-24-108914.json
- Plain text: https://secwatch.observer/filing/0001104659-24-108914.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.